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ABSTRACT
Insulin degludec/insulin aspart (IDegAsp) is the
first soluble co-formulation which combines
two insulin analogues, and provides effective
basal and prandial glycemic coverage. It has
been assessed as basal insulin in type 2 diabetes
mellitus (T2DM), and as part of basal-bolus
regime in both type 1 diabetes mellitus and
T2DM. Insulin degludec has also been assessed
as flexibly administered basal insulin in terms of
time of administration. This review discusses
data pertaining to the efficacy, safety,
tolerability, and clinical potential of IDegAsp.
The discussion includes comparisons of
IDegAsp with basal as well as premixed insulin.




Recent years have seen great advances in insulin
pharmacotherapeutics. The development of
insulin analogues has helped to achieve
greater safety and tolerability in treatment of
diabetes [1, 2]. Currently available analogues
include the rapidly-acting insulin aspart (IAsp),
lispro and glulisine; the long-acting glargine
(IGlar); and ultra-long-acting degludec (IDeg),
which is a recently developed basal insulin
analogue, described earlier in Diabetes
Therapy [3].
Currently available basal and bolus
analogues offer basal and precise postprandial
glucose control but are administered as separate
injections [4, 5]. Many patients are reluctant to
start with a basal and bolus insulin regimen.
Patients and physicians are concerned about the
risk of hypoglycemia [6, 7]. Multiple insulin
injections increase patients’ treatment burden,
and the burden of multiple injections may limit
adherence [8, 9].
A co-formulation of basal and bolus insulin
could allow for a simple regimen providing
both basal and mealtime coverage with fewer
injections than basal and bolus therapy.
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Insulin degludec/insulin aspart (IDegAsp) is
a recently developed soluble co- formulation
containing two insulin analogues: 30% of
short-acting analogue IAsp and 70% basal
analogue IDeg. In a model of the
subcutaneous environment [10], IDeg forms
distinct multi-hexamers that are slowly
absorbed, while IAsp immediately forms
monomers that are rapidly absorbed. This
indicates that the basal (IDeg) and prandial
(IAsp) components do not interact and their
distinct pharmacokinetic/pharmacodynamics
profiles are not compromised by co-
formulation [11].
This review discusses currently available
evidence related to this novel co-formulation,
and describes its future potential.
CLINICAL TRIAL PROGRAMME
The IDegAsp clinical trial programme builds
upon the extensive studies conducted for IDeg.
IDeg has been studied in phase 3a and 3b trials,
conducted in both type 1 diabetes mellitus
(T1DM) and type 2 diabetes mellitus (T2DM)
subjects [12, 13]. It has been assessed as basal
insulin in T2DM, and as part of basal-bolus
regime in both T1DM and T2DM [13, 14,]. IDeg
has also been assessed as flexibly administered
basal insulin in terms of time of dosages
[15, 16].
The IDegAsp clinical trial programme,
named BOOST (clinical trial number: 3594),
studied this molecule in T1DM, comparing it
with a basal-bolus regime [17]. In T2DM,
IDegAsp once daily has been analysed as an
initiation as well as intensification strategy [18,
19]. IDegAsp twice daily has also been studied as
an intensification treatment in T2DM insulin
users [20, 21]. Results published from various
studies in the BOOST family provide an




In a 16-week-long, open-label, randomised
controlled trial, once-daily IDegAsp was
compared with IGlar, both combined with
metformin [18].
This treat-to-target study aimed to achieve a
primary fasting plasma glucose (FPG) target of
4.0–6.0 mmol/L, and a secondary target post-
dinner plasma glucose of \8.0 mmol/L,
provided that no hypoglycemic episode had
taken place. A starting dose of 10 U/day of
insulin was used [18].
There was a third arm which assessed an
alternative formulation, this has since been
withdrawn from development. Both IDegAsp
arms achieved 0.11% higher HbA1c reduction
vs. IGlar; however, this was not statistically
significant. A similar proportion of subjects was
able to achieve target HbA1c without confirmed
hypoglycemia in the last 4 weeks of the trail
[18]. This can be explained by slightly better
FPG reduction with IDegAsp as compared to
IGlar (mean difference 0.13 mmol/L). IDegAsp
was able to achieve a lower post-dinner glucose
increment than IGlar (0.13 vs. 1.63 mmol/L,
respectively), without increasing the risk of
hypoglycemia, in spite of a lower insulin dose
(0.38 ? 0.16 vs. 0.45 ? 0.20 U/kg for IDegAsp
and IGlar, respectively) [18].
Another method of checking glycemic
control is to perform continuous glucose
monitoring (CGM) of interstitial fluid. This
allows one to assess interstitial glucose (IG)
concentrations and fluctuations, measure IG
peaks, increments and lows, and calculate
intra-individual coefficient of variation. IG
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monitoring is a more efficient way of assessing
the safety of various antihyperglycemic drugs,
as it provides an accurate, measurement of
hyperglycemic as well as hypoglycemic
episodes.
A subset of 112 insulin-naı¨ve T2DM patients
was enrolled in an open-label, randomised,
parallel-group trial comparing IDegAsp with
IGlar. Patients were included if they were
insulin-naı¨ve adults (18–75 years of age) with
T2DM, had HbA1c of 7–11% and body mass
index of 25–37 kg/m2, and were treated with up
to two oral antihyperglycemic drugs (excluding
thiazolidinediones) in the 2 months prior to
trial at stable maximum doses or at least half
maximum allowed doses [22]. Patients were
subject to IG monitoring for 72-h-long periods,
after 8 and 16 weeks of treatment. This was in
addition to the 9-point self-monitoring plasma
glucose (SMPG) profile performed by the
patients. At baseline HBA1c in IDegAsp and
IGlar groups was 8.4 ± 1.3% and 8.3 ± 1.2%,
respectively. The insulin starting dose was 10
U/day IDegAsp, administered using a 3 mL
FlexPen device (Novo Nordisk A/S, Bagsværd,
Denmark); IGlar was administered using a 3 mL
OptiSet device (sanofi-aventis, Paris, France).
Insulin was continuously titrated, aiming for an
FPG target of 4.0–6.0 mmol/L (72–108 mg/dL),
and if this goal was achieved, a post-dinner
plasma glucose target of 8.0 mmol/L (145 mg/
dL) was additionally set. The three 24-h
intervals assessed by CGM at 16 weeks were
reported upon. The mean IG concentration was
similar for both IDegAsp and IGlar (8.10 and
8.31 mmol/L, respectively). Mean nocturnal IG
concentration (IDegAsp 7.26 mmol/L and IGlar
7.75 mmol/L) and coefficient of variation of
mean nocturnal IG (IDegAsp 19.3% and IGlar
20.2%) were similar for IDegAsp and IGlar. The
mean post-dinner glucose increment for IGlar
and IDegAsp was 1.15 and -0.38 mmol/L,
respectively, which was significantly lower for
IDegAsp, with an estimated treatment
difference of 1.42 mmol/L (95% confidence
interval -2.15, -0.70) as compared to IGlar
[22].
IDegAsp use was associated with a
statistically significant lesser mean fluctuation
in nocturnal IG [1.13 vs. 1.30 mmol/L with
IGlar; estimated treatment ratio (ETR) = 0.79.
95% confidence interval (CI) 0.66, 0.96], and in
IG over the 4- to 12-h period following dinner
(ETR = 0.80; 95% CI 0.66, 0.96) [22]. The
frequency and duration of hypoglycemic
episodes were similar in both arms, but there
was a statistically significant reduction in high
IG nocturnal episodes with IDegAsp
(ETR = 0.52, 95% CI 0.32, 0.37). The results of
this study, which uses novel, modern CGM
technology, are consistent with those obtained
from 9-point SMPG in the parent study [22].
The lack of postprandial glucose increment with
IDegAsp, however, drives home the utility of
adding a prandial or rapid-acting component to
basal insulin. Demonstration of uniform
glycemic response at night, without increasing
the risk of hypoglycemia, is reassuring [22].
Onishi et al. [19] published data from a study
conducted in Japanese subjects. In this treat to
target protocol, 296 insulin-naı¨ve adults with
T2DM discontinued all sulfonylureas, glinides
and dipeptidyl peptidase 4 inhibitors, while
continuing other oral antihyperglycemic drugs
after being randomised to initiate either
IDegAsp or IGlar with a starting dose of 10 U/
day. IDegAsp was injected just prior to the
largest meal of the day (chosen at discretion of
the subject) while IGlar was taken at a fixed
time daily, either before breakfast or at bedtime.
At the end of the 26 week study, IDegAsp
demonstrated a reduction in HbA1c [final
HbA1c 7.0% for IDegAsp vs. 7.3% for IGlar.
Estimated treatment difference (ETD) of 0.28%,
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95% CI -0.46, -0.10: P\0.01]. While mean
FPG, change in body weight (0.7 kg) and insulin
doses (0.41 U/kg) were similar in both groups,
IDegAsp users experienced numerically lesser
rates of confirmed and nocturnal confirmed




Nishanen et al. [23] studied insulin-naı¨ve
subjects with T2DM inadequately controlled
on oral antihyperglycemic drug therapy. This
study was a 16-week exploratory trial
comparing the efficacy and safety of IDegAsp
with biphasic IAsp 30 (BIAsp 30), both given
twice daily in combination with metformin.
Patients were randomised to three groups:
either IDegAsp, BIAsp 30, or alternative
formulation of IDeg/IAsp which were
administrated twice daily, before breakfast and
dinner in combination with metformin. Mean
age was 58.7, 60.5 and 59.7 years for each
treatment group, respectively. Mean HBA1c
among the three groups was 8.5, 85 and 8.6%,
respectively. Mean FPG levels at baseline among
the three groups were also similar. Mean HbA1c
achieved was comparable in all three groups;
however, 67% of IDegAsp-treated subjects
achieved an HbA1c \7.0% without confirmed
hypoglycemia in the last 4 weeks of treatment,
as compared to 40% with BIAsp 30. The
IDegAsp group had significantly lower FPG
(ETD—0.99 mmol/L; 95% CI -1.68; 0.29),
lower confirmed hypoglycemia [relative risk
(RR) 0.42; 0.25, 0.75] and numerically lower
nocturnal confirmed hypoglycemia (RR 0.33;
0.09, 1.14) as compared to the BIAsp 30 cohort.
Pre-breakfast and pre-dinner SMPG targets were
achieved in the absence of confirmed
hypoglycemia by 81% and 43% of IDegAsp- and
BIAsp 30-treated subjects, respectively. The
median time taken to achieve these targets
was 8 weeks for IDegAsp and 13 weeks for
BIAsp 30. By trial end, the daily dose
requirement of IDegAsp was 13% lower
(0.57 ± 0.23 U/kg), as compared to BIAsp 30
(0.66 ± 0.30 U/kg), though metformin dose was
similar (2,000 mg/day) [23].
In a 26-week, phase 3, open-label,
randomised, treat-to-target trial presented by
Fulcher et al. [20], the efficacy of IDegAsp was
compared to BIAsp 30 in patients with poor
control in spite of taking once daily or twice
daily, premixed or self-mixed insulin. In the
IDegAsp and BIAsp 30 treatment groups, the
mean age of patients was 58.7 and 58.8 years,
respectively. Mean HBA1c at baseline was 8.3%
in the IDegAsp treatment group and 8.4% in the
BIAsp 30 treatment group, and mean FPG at
baseline was 8.9 and 8.6 mmol/dL in IDegAsp
and BIAsp 30 groups, respectively. At the end of
the trial, mean change from baseline in HbA1c
for IDegAsp treatment after 26 weeks was non-
inferior to BIAsp 30 (ETD -0.03%, 95% CI
-0.18; 0.13); however, IDegAsp was superior to
BIAsp 30 in lowering FPG [ETD 1.14 mmol/L,
(-1.53 to 0.76) P\0.01] while producing less
weight gain (1.7 vs. 2.2 kg, ETD 0.62 kg), using
lower dose [1.08 vs. 1.2 U/kg, RR 0.89 (0.83,
0.96), P\0.002]. IDegAsp was also associated
with lower rates of confirmed hypoglycemia
compared to BIAsp 30 [IDegAsp 9.7 vs. BIAsp 30
14 episodes per year (EPY), RR 0.68 (0.52,
0.89) P\0.002] and confirmed nocturnal
hypoglycemia [IDegAsp 0.7 vs. BIAsp 30 2.5
EPY, RR 0.27 (0.18, 0.41), P\0.0001] [20].
Another study compared IDegAsp and BIAsp
30 in Asian subjects, poorly controlled on either
basal or mixed insulin, with or without
metformin [21]. Mean age in the IDegAsp
treatment group was 59.1 and 61.2 years in
the BIAsp 30 treatment group. Mean HBA1c at
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baseline was 8.4% and 8.4% for the IDegAsp
and BIAsp 30 treatment groups, respectively,
and mean FPG at baseline was 7.9 and
7.9 mmol/L in IDegAsp and BIAsp 30 groups,
respectively. After 26 weeks, mean HbA1c for
IDegAsp and BIAsp 30 was 7.1% vs. 7.0%,
respectively IDegAsp was non-inferior to BIAsp
30 (ETD 0.05% 95% CI -0.10; 0.20). The non-
inferiority of IDegAsp to BIAsp 30 in terms of
HbA1c control was achieved with a lower daily
dose [IDegAsp 0.79 U/kg vs. BIAsp 300.99 U/kg,
RR 0.79 (0.73, 0.85)]. FPG levels were also
significantly lower in the IDegAsp cohort [16].
The risk of severe hypoglycaemia was similar in
IDegAsp group vs. BIAsp 30. The risk of
nocturnal hypoglycaemia was numerically
lower but not statistically significant. The
robust reduction in hypoglycemia seen with
the aforementioned Fulcher et al. study [20] was
not seen in this study. The benefit of weight
reduction seen in Fulcher et al. [20] was also not
evident.
USE IN TYPE 1 DIABETES
IDegAsp has also been studied in people with
T1DM. It maintains its distinct prandial and
basal pharmacodynamics in elderly subjects
(age C65 years) [24, 25]. In a 26-week-long,
phase 3 randomised, open-label, treat-to-target
trial, IDegAsp was prescribed once daily at any
meal, with IAsp at other meals, creating an
innovative three dose regime. This was
compared with a standard basal-bolus regime
using three doses of aspart and one or two doses
of detemir per day. The IDegAsp basal regime
was non-inferior to the standard basal-bolus
regime in terms of HbA1c reduction, though it
had a 13% lower dose requirement (69 U and
0.86 U/kg vs. IDet 79 U and 1.00 U/kg;
P\0.0001) [17]. It was also associated with
37% less nocturnal confirmed hypoglycemia
[IDegAsp 3.71 vs. standard basal-bolus regime
5.72 EYP, (P\0.05)], and led to more weight
gain (2.3 vs. 1.3 kg (P\0.05). This study
demonstrates the efficacy of this three dose
regime, including IDegAsp in T1DM [17].
Though not studied yet, it creates the hope
for use of a convenient regime, using two doses
of IDegAsp, in persons with T1DM, who
currently have to take 4–5 injections per day
with conventional insulins [18]. Such a regime
will also be useful for patients with T2DM, who
require intensification with basal-bolus therapy,
but do not wish to take multiple injections.
CLINICAL POTENTIAL
IDegAsp has demonstrated its utility in the
management of both T1DM and T2DM. In
T1DM, it heralds the beginning of an era of
convenient, effective three dose regime, which
will replace currently used four or five dose based
intensive therapies. In T2DM, it offers the
advantage of lower hypoglycemia, and greater
safety [16, 17]. This is achieved with lesser or
equal dose requirement. This advantage
will allow IDegAsp to be used as insulin of
choice while initiating therapy. Current
American Diabetes Association (ADA)/European
Association for study of Diabetes (EASD)
guidelines recommend only basal insulin for
this purpose, citing the ‘‘inconvenience’’, lack of
flexibility, and risk of hypoglycemia associated
with conventional premixed insulins [20].
IDegAsp overcomes these arguments against the
use of premixed insulin. It is convenient and
flexible to use, as it can be administered with any
major meal, irrespective of time. It can also be
used once daily or twice daily, with a reduced risk
of hypoglycemia than currently available insulin
[16, 17]. It has been studied in combination with
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various oral antihyperglycemic drugs [15].
Though not yet approved in the United States,
IDeg is an approved drug in Europe, Japan
Mexico, India, and other countries as well.
The definition of hypoglycemia of 3.1 mmol/
L (56 mg/dL) and the FPG targets of 4–5 mmol/L
(71–89 mg/dL) used in the phase 3a clinical
development is debatable [14–17]. Titrating to
such stringent targets may not reflect what is
routinely followed in clinical practice. Since
IDegAsp may be looked at as good option for
intensification following a failure of basal only
therapy, there is a need to compare twice
daily IDegAsp with basal plus strategy of
intensification. But currently, no such data is
published. At present, the safety of IDegAsp has
not been proven in patients aged less than
18 years and also in pregnancy. Therefore, the
applicability of IDegAsp in T1DM and in
gestational diabetes mellitus is limited.
Despite the fact that IDegAsp is a novel soluble
co-formulation and offers convenience to the
patients, similar to premixed insulins, it is not
possible to adjust the dose of prandial and basal
components separately. There are also no studies
to compare basal-bolus therapy with twice daily
IDegAsp in T2DM patients. Such studies are
currently available only in T1DM patients.
The use of IDegAsp as an initiation therapy
can be in once daily or twice daily doses based
upon the clinical situation. It can be prescribed
as monotherapy or in combination with
metformin. T2DM patients switching from
once-daily basal or premix insulin therapy can
be converted unit-to-unit to once-daily IDegAsp
at the same total insulin dose as the patient’s
previous total daily insulin dose. Patients
switching from more than once-daily basal or
premix insulin therapy can be converted unit-
to-unit to twice-daily IDegAsp at the same total
insulin dose as the patient’s previous total daily
insulin dose. Patients switching from basal-
bolus insulin therapy to IDegAsp will need to
convert their dose based on individual needs. In
general, patients are initiated on the same
number of basal units. In patients with T1DM,
the recommended starting dose of IDegAsp is
60–70% of the total daily insulin requirements
in combination with short-/rapid-acting insulin
at the remaining meals followed by individual
dosage adjustments [21]. It is recommended
that titration should be based upon monitoring
of plasma glucose: the morning dose
requirement of IDegAsp may be lower than
the dinner dose. Switching from twice daily
premixed insulin to two doses of IDegAsp
should prompt a 10–20% reduction in initial
dose (Table 1). A patient centric approach
should be followed while choosing initial
doses and up-titrating them.
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